Abstract
SAT158 - Novel avenue towards liver regeneration and treatment of acute and chronic liver diseases: safety and PK profile from a first-in human (FIH) clinical trial for HRX-0215 as first in class MKK4 inhibitor
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
